1.	German Multicenter Trial for Treatment of Newly Diagnosed Acute Lymphoblastic Leukemia in Adults (07/2003) Phase: Phase IV Type: Treatment Status: Active Age: 15 to 65 Sponsor: Other Protocol IDs: GMALL01, NCT00198991
2.	Efficacy of G-CSF-Priming in Elderly AML Patients Phase: Phase IV Type: Treatment Status: Active Age: Over 60 Sponsor: Other Protocol IDs: AML-elderly 01/99 Trial, NCT00199147
3.	Busulfan Safety/Efficacy as Conditioning Prior to Hematopoietic Cell Transplantation (HCT) Phase: Phase IV Type: Treatment Status: Active Age: 16 to 65 Sponsor: Other Protocol IDs: MCC-14178, NCT00361140
4.	Allogeneic Transplantation for Pediatric Leukemias With Unrelated Donors Phase: Phase IV Type: Treatment Status: Active Age: 21 and under Sponsor: Other Protocol IDs: SCT 0208, NCT00679536
5.	Phase II/III Study of Standard and Novel Conditioning Therapy Followed By Allogeneic Stem Cell Transplantation in Patients With Severe Aplastic Anemia or Hematologic Malignancy Phase: Phase III, Phase II Type: Treatment Status: Active Age: 4 to 70 Sponsor: Other Protocol IDs: RPCI-RP-9815, NCI-V99-1527, NCT00003816, RP 98-15
6.	Nonmyeloablative Stem Cell Transplant in Elderly Phase: Phase III, Phase II Type: Treatment Status: Active Age: Over 60 Sponsor: Other Protocol IDs: 012000, NCT00382759
7.	Lumiliximab With Fludarabine, Cyclophosphamide, and Rituximab (FCR) Versus FCR Alone in Subjects With Relapsed Chronic Lymphocytic Leukemia (CLL) Phase: Phase III, Phase II Type: Treatment Status: Active Age: 18 and over Sponsor: Pharmaceutical / Industry Protocol IDs: 152CL201, NCT00391066
8.	Phase II/III Randomized Study of Combination Chemotherapy With or Without Gemtuzumab Ozogamicin or Tipifarnib in Patients With Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndromes Phase: Phase III, Phase II Type: Biomarker/Laboratory analysis, Treatment Status: Active Age: Any age Sponsor: Other Protocol IDs: UHW-AML16, EU-20677, ISRCTN11036523, EUDRACT-2005-002846-14, MREC-CU106, NCT00454480
9.	Non-Myeloablative Allogeneic HSCT From HLA Matched Related Donors for the Treatment of Low Grade B Cell Malignancies Phase: Phase III, Phase II Type: Treatment Status: Active Age: 19 to 70 Sponsor: Other Protocol IDs: F080429003, UAB-0775, NCT00714259
10.	Phase III Randomized Study of Nonmyeloablative Conditioning Comprising Low-Dose Total Body Irradiation With Versus Without Fludarabine Followed By HLA-Matched Related Allogeneic Hematopoietic Stem Cell Transplantation in Patients With Hematologic Malignancies at Low or Moderate Risk For Graft Rejection Phase: Phase III Type: Treatment Status: Active Age: Under 75 Sponsor: NCI Protocol IDs: FHCRC-1813.00, 5666, NCT00075478
11.	Phase 3 Trial for AML Patients in CR2 Comparing 8Gy TBI /Fludarabine to Conditioning With TBI 12Gy/Cyclophosphamide Phase: Phase III Type: Treatment Status: Active Age: 18 to 60 Sponsor: Other Protocol IDs: AML_CR2_allo_HSCT, NCT00125606
12.	Standard vs. Reduced-Intensity Conditioning in Patients With Acute Myeloid Leukemia in First Remission Phase: Phase III Type: Treatment Status: Active Age: 18 to 60 Sponsor: Other Protocol IDs: 9005-2003, NCT00150878
13.	To Determine the Role of Adding Campath-1H or ATG Given in-Vivo in Addition to Fludarabine and Low Dose Busulfex on Outcome in Patients Treated With Reduced Intensity Conditioning Phase: Phase III Type: Treatment Status: Active Age: 18 and over Sponsor: Other Protocol IDs: 230704-HMO-CTIL, NCT00226512
14.	Randomised Prospective Comparison of the NMA Allograft and the Traditional Allograft in Acute Myeloid Leukaemia Phase: Phase III Type: Treatment Status: Active Age: 35 to 55 Sponsor: Other Protocol IDs: P040420, AOM04088, NCT00224614
15.	Rituximab After Induction Chemotherapy (R-CHOP Vs. R-FC) Followed by Interferon Maintenance Versus Rituximab Maintenance in Mantle Cell Lymphoma Phase: Phase III Type: Treatment Status: Active Age: 60 and over Sponsor: Other Protocol IDs: MCL2004-1, NCT00209209
16.	Treatment of Children and Adolescents With Refractory or Relapsed Acute Myeloid Leukemia Phase: Phase III Type: Treatment Status: Active Age: 17 and under Sponsor: Other Protocol IDs: TRIAL, TRIAL Relapsed AML 2001/01, NCT00186966
17.	Phase III Study of Fludarabine and Darbepoetin alfa in Geriatric Patients With Chronic Lymphocytic Leukemia and Comorbidities Phase: Phase III Type: Treatment Status: Active Age: Geriatric Sponsor: Other, Pharmaceutical / Industry Protocol IDs: GCLLSG-CLL9, EU-20561, AMGEN-GCLLSG-CLL9, EUDRACT-2005-003014-15, NCT00281892
18.	Phase III Randomized Study of Rituximab, Fludarabine, and Cyclophosphamide Versus Observation Only in Patients With High-Risk, Previously Untreated Binet Stage A B-Cell Chronic Lymphocytic Leukemia Phase: Phase III Type: Treatment Status: Active Age: 18 and over Sponsor: Other, Pharmaceutical / Industry Protocol IDs: GCLLSG-CLL7, EU-20559, ROCHE-GCLLSG-CLL7, EUDRACT-2005-003-018-14, NCT00275054
19.	Phase III Randomized Study of Myeloablative Versus Nonmyeloablative Transplant Conditioning in Patients With Myelodysplastic Syndromes or Acute Myeloid Leukemia Phase: Phase III Type: Treatment Status: Active Age: 65 and under Sponsor: NCI, NHLBI Protocol IDs: FHCRC-1992.00, 6170, NCT00322101, NHLBI-K23-HL084054-01A1
20.	Phase III Randomized Study of Early Versus Delayed Chemoimmunotherapy Comprising Fludarabine Phosphate and Rituximab in Patients With Asymptomatic, Previously Untreated Chronic Lymphocytic Leukemia Phase: Phase III Type: Biomarker/Laboratory analysis, Treatment Status: Active Age: 18 and over Sponsor: NCI Protocol IDs: CALGB-10501, CALGB-10501, NCT00513747
21.	Single Versus Double Umbilical Cord Blood Transplantation in Children With High Risk Leukemia and Myelodysplasia Phase: Phase III Type: Treatment Status: Active Age: 1 to 21 Sponsor: NCI, NHLBI Protocol IDs: 467, BMT CTN 0501, 5 U01 HL69294-05, NCT00412360
22.	IV Busulfan With Allo-BMT: Study for Patients With Acute Myelogenous Leukemia and Myelodysplastic Syndrome Phase: Phase III Type: Biomarker/Laboratory analysis, Treatment Status: Active Age: 65 and under Sponsor: Other Protocol IDs: 2005-0366, NCT00469144
23.	Phase III Randomized Study of First-Line Therapy Comprising Chlorambucil Versus Fludarabine Phosphate in Patients With Previously Untreated Waldenström Macroglobulinemia, Splenic Lymphoma With Villous Lymphocytes, or Non-IgM Lymphoplasmacytic Lymphoma Phase: Phase III Type: Treatment Status: Active Age: 18 and over Sponsor: Other Protocol IDs: TSH-WM1, ISRCTN56052618, TSH-WM1, NCT00608374
24.	Allogenic Stem Cell Transplantation for Children, Adolescents and Young Adults With Relapsed or Refractory AML Phase: Phase III Type: Treatment Status: Approved-not yet active Age: 21 and under Sponsor: Other Protocol IDs: AML SCT-BFM 2007, EudraCT: 2007-004517-34, NCT00606723
25.	Phase III Randomized Study of Fludarabine Phosphate and Cyclophosphamide With Versus Without Rituximab in Patients With Previously Untreated Mantle Cell Lymphoma Phase: Phase III Type: Biomarker/Laboratory analysis, Treatment Status: Active Age: 18 and over Sponsor: Other Protocol IDs: CRUK-UCL-MCLIII, CRUK-UCL-MCLIII, EUDRACT-2006-001965-41, MREC-02/6/31, EU-20824, NCT00641095